Portulaca oleracea, ext. | CAS:90083-07-1

We serve Portulaca oleracea, ext. CAS:90083-07-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Portulaca oleracea, ext.

Chemical Name:Portulaca oleracea, ext.
CAS.NO:90083-07-1
Synonyms:Portulaca oleracea, ext.
PORTULACA OLERACEA EXTRACT
 
Specification:
Appearance:Light amber liquid or brown powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Purslane (Portulaca Oleracea) Extract has the effect Antiallergy, stimulation, anti-inflammatory and acne, widely used in cosmetic and skin care products such as Cleanser, lotion, cream, emulsion and wax, etc., especially suitable for men's skin care product, is used to eliminate the razor after burning, irritation and redness. PPurslane (Portulaca Oleracea) Extract than Chamomile Extract and Dipotassium Glycyrrhizinate is more suitable for use in cosmetics.



Contact us for information like Portulaca oleracea, ext. chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,PORTULACA OLERACEA EXTRACT physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,PORTULACA OLERACEA EXTRACT Use and application,PORTULACA OLERACEA EXTRACT technical grade,usp/ep/jp grade.


Related News: Chinese nationals coming from China and connecting through another foreign airport will be denied travel. Those with pre-clearance are exempted.(9-(naphthalen-1-yl)-9H-carbazol-3-yl)boronic acid manufacturer The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.3-Amino-1,2-propanediol supplier We manufacture APIs and drug manufacturers make medicines from APIs.2,3,6-TRIFLUOROBENZOIC ACID vendor We manufacture APIs and drug manufacturers make medicines from APIs.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.